Description
AMG-228 is under investigation for its potential use in colorectal cancer, particularly in patients with mutations or amplifications of the FGFR pathway; however, it has not yet been approved by regulatory agencies and clinical data on efficacy in CCR are limited to early-phase trials.
Mechanism of Action
AMG-228 is an investigational drug that targets the FGFR (fibroblast growth factor receptor) pathway, which plays a role in cell proliferation and survival; it inhibits FGFR signaling by blocking ATP binding to the kinase domain of FGFRs.
Side Effects
Fatigue; nausea; diarrhea; vomiting; constipation
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
NCT02437916
Phase 1
Archived
Safety Study of AMG 228 to Treat Solid Tumors
United States, Australia, Belgium, France, Germany